Business Description
FibroBiologics Inc
NAICS : 541713
SIC : 2833
ISIN : US31573L1052
Total Employee Number:
15Description
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.6 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.95 | |||||
Debt-to-EBITDA | -0.14 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -43.1 | |||||
3-Year EPS without NRI Growth Rate | -39.5 | |||||
3-Year FCF Growth Rate | -43.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 48.27 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.96 | |||||
9-Day RSI | 48.2 | |||||
14-Day RSI | 44.35 | |||||
3-1 Month Momentum % | -32.04 | |||||
6-1 Month Momentum % | -86.24 | |||||
12-1 Month Momentum % | -92.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.59 | |||||
Quick Ratio | 1.59 | |||||
Cash Ratio | 0.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27 | |||||
Shareholder Yield % | -21.71 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -772.48 | |||||
ROA % | -188.18 | |||||
ROIC % | -220.12 | |||||
3-Year ROIIC % | 274.99 | |||||
ROC (Joel Greenblatt) % | -562.9 | |||||
ROCE % | -458.39 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.16 | |||||
Price-to-Tangible-Book | 1.16 | |||||
EV-to-EBIT | -0.34 | |||||
EV-to-Forward-EBIT | -3 | |||||
EV-to-EBITDA | -0.35 | |||||
EV-to-FCF | -0.4 | |||||
Earnings Yield (Greenblatt) % | -294.12 | |||||
FCF Yield % | -300.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FBLG
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
FibroBiologics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -6.93 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 100.86 | ||
| 14-Day RSI | 44.35 | ||
| 14-Day ATR ($) | 0.084071 | ||
| 20-Day SMA ($) | 0.838765 | ||
| 12-1 Month Momentum % | -92.6 | ||
| 52-Week Range ($) | 0.731 - 14.678 | ||
| Shares Outstanding (Mil) | 6.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
FibroBiologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
FibroBiologics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-30 | In 108 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 17 days | ||
| H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | 2026-06-30 13:00 | 0.79 (-0.38%) | ||
| General meeting for 2026 | 2026-06-22 11:00 | 0.77 (-6.07%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 1.31 (-5.07%) | ||
| 0.05:1 Stock Split | 2026-03-30 | 3.93 (-8.56%) | ||
| Annual report for 2025 | 2026-02-24 | 5.06 (+4.98%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-24 | 5.06 (+4.98%) | ||
| Third quarter earnings results for 2025 | 2025-10-31 | 7.94 (-2.00%) | ||
| Guidance call for 2025 | 2025-10-07 14:15 | 11.00 (+1.81%) |
Show
Entries
FibroBiologics Inc Frequently Asked Questions
What is FibroBiologics Inc(FBLG)'s stock price today?
The current price of FBLG is $0.86. The 52 week high of FBLG is $14.68 and 52 week low is $0.73.
When is next earnings date of FibroBiologics Inc(FBLG)?
The next earnings date of FibroBiologics Inc(FBLG) is 2026-07-31 Est..
Does FibroBiologics Inc(FBLG) pay dividends? If so, how much?
FibroBiologics Inc(FBLG) does not pay dividend.
Guru Commentaries on NAS:FBLG
No articles.
Press Release
Articles on FibroBiologics Inc
Headlines
See More- 1
Jun 26, 2026
FibroBiologics prices up to $9M private placement
Seeking Alpha • 7:47am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers